Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes

志愿者 抗体 医学 相(物质) 免疫学 生物 化学 农学 有机化学
作者
François Philippe,Philippe Couttet,И. Ф. Демин,Birgit Jaitner,Yinuo Pang,Ronenn Roubenoff,Esther Sutter,Yoav E. Timsit,Marie Anne Valentin,Beate Vogel,G. Woerly,Armin Wolf,Ursula Schramm
出处
期刊:Journal of Pharmacology and Experimental Therapeutics [American Society for Pharmacology & Experimental Therapeutics]
卷期号:369 (3): 428-442 被引量:11
标识
DOI:10.1124/jpet.118.254128
摘要

The colony-stimulating factor-1 (CSF-1) receptor pathway has been implicated in a variety of diseases, and CSF-1-dependent mechanisms are also involved in bloodborne protein clearance. Lacnotuzumab is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1-mediated receptor activation. This phase 1, two-part, double-blind study in healthy volunteers assessed the safety and tolerability of lacnotuzumab and its pharmacokinetics (PK) and pharmacodynamic properties. Part A (n = 36) was a single, ascending-dose assessment of eight lacnotuzumab doses (0.01-20 mg/kg); in part B (n = 16), lacnotuzumab was administered at either 5 or 10 mg/kg. In each study cohort, individuals were randomized 3:1 to lacnotuzumab or placebo. Lacnotuzumab was generally well tolerated. At higher doses (10 and 20 mg/kg), creatine kinase (CK) elevations (>5× the upper limit of normal, but asymptomatic and reversible) and mild transient periorbital swelling were reported. Most adverse events (AEs) were low-grade, no unexpected or novel AEs were observed, and there were no discontinuations for AEs. Free, unbound lacnotuzumab serum concentration-time profiles showed nonlinear PK across doses from 0.01 to 20 mg/kg, with faster apparent elimination at lower doses or concentrations; this finding was consistent with apparent target-mediated drug disposition. Lacnotuzumab also showed dose-dependent, on-target effects on multiple downstream biomarkers. Preclinical investigations of the CK elevation and periorbital swelling observed after lacnotuzumab administration suggest that these are reversible, nonpathological events linked to inhibition of the CSF-1 pathway. These data support further evaluation of lacnotuzumab in clinical studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
acc关注了科研通微信公众号
2秒前
人不如故发布了新的文献求助10
2秒前
Gauss应助shyy采纳,获得40
3秒前
5秒前
cz完成签到 ,获得积分10
5秒前
6秒前
9秒前
靜-沉发布了新的文献求助10
9秒前
阿科完成签到,获得积分20
10秒前
10秒前
淡定的素发布了新的文献求助10
12秒前
阿科发布了新的文献求助10
14秒前
acc发布了新的文献求助10
15秒前
雪白的豪英完成签到 ,获得积分10
16秒前
踏实碧琴完成签到,获得积分10
17秒前
JAMES完成签到 ,获得积分10
20秒前
思源应助淡定的素采纳,获得10
21秒前
Silence完成签到 ,获得积分10
24秒前
QMCL完成签到,获得积分10
25秒前
烟花应助踏实凌珍采纳,获得10
26秒前
养头猪饿了吃完成签到,获得积分10
26秒前
Ray发布了新的文献求助10
27秒前
Dusk大寺柯完成签到 ,获得积分10
27秒前
stretchability完成签到 ,获得积分10
28秒前
低调的魔术师完成签到,获得积分20
29秒前
不会打预防针完成签到,获得积分10
30秒前
manman发布了新的文献求助10
31秒前
rocky15应助激情的三毒采纳,获得10
34秒前
678完成签到 ,获得积分10
34秒前
去火星种一颗芋头应助lzs采纳,获得100
35秒前
小蘑菇应助Anar采纳,获得10
36秒前
低调的魔术师关注了科研通微信公众号
38秒前
39秒前
开朗的翠彤完成签到,获得积分10
39秒前
空2完成签到 ,获得积分10
42秒前
酷酷河马完成签到,获得积分10
43秒前
冷酷的风华完成签到 ,获得积分10
47秒前
Minicoper发布了新的文献求助30
47秒前
酉时之水完成签到,获得积分10
47秒前
ding应助俏皮的半夏采纳,获得10
49秒前
高分求助中
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
行動データの計算論モデリング 強化学習モデルを例として 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2546745
求助须知:如何正确求助?哪些是违规求助? 2175896
关于积分的说明 5601536
捐赠科研通 1896703
什么是DOI,文献DOI怎么找? 946382
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503569